Company Filing History:
Years Active: 2024
Title: Chenyu Shu: Innovator in Cancer Treatment
Introduction
Chenyu Shu is a prominent inventor based in Jiangsu, China. He has made significant contributions to the field of cancer treatment through his innovative work on single-domain antibodies. His research focuses on developing targeted therapies that can improve patient outcomes in cancer care.
Latest Patents
Chenyu Shu holds a patent for "Single-domain antibodies against CLL1 and constructs thereof." This patent includes single-domain antibodies targeting CLL1, along with constructs such as chimeric receptors, immune effector cell engagers, and immunoconjugates. The invention also encompasses engineered immune effector cells, including T cells, that comprise an anti-CLL1 chimeric receptor. Additionally, it provides pharmaceutical compositions, kits, and methods for treating cancer.
Career Highlights
Chenyu Shu is currently employed at Legend Biotech Ireland Limited, where he continues to advance his research in immunotherapy. His work is pivotal in the development of novel cancer treatments that harness the body's immune system to fight cancer more effectively.
Collaborations
Chenyu Shu collaborates with notable colleagues, including Wang Zhang and Yunlei Liu, who contribute to his research efforts and the advancement of cancer therapies.
Conclusion
Chenyu Shu's innovative work in developing single-domain antibodies represents a significant advancement in cancer treatment. His contributions are vital for the future of targeted therapies in oncology.